Gosset Employees
~50
Stage
Commercial
Modalities
Intrinsic Therapeutics General Information
The company's Barricaid Anular Closure Device received FDA approval in 2019 based on a multicenter level I RCT demonstrating superior outcomes to discectomy alone. Clinical studies show significantly reduced disc reherniations and reoperations compared to conventional lumbar discectomy.
Contact Information
Drug Pipeline
Barricaid
CommercialKey Partnerships
Intrinsic Therapeutics Funding
| Deal Type | Date | Amount | Status | Stage |
|---|
To view Intrinsic Therapeutics's complete valuation and funding history, request access »